Precision BioSciences Shows First Evidence Of CccDNA Elimination In Hepatitis B Patients; Stock Up
Precision BioSciences (DTIL) reported first clinical biopsy evidence from its ELIMINATE-B study that PBGENE-HBV can eliminate and inactivate hepatitis B cccDNA. The company said cccDNA transcripts fell 10-fold after two doses, with remaining cccDNA showing indels that disrupt viral polymerase. It also reported pgRNA as a biomarker and durable HBsAg declines up to a year; 38 doses in 16 patients showed no dose-limiting toxicities.
How this was made
The 30-second read
Why it matters
The reported 10-fold cccDNA transcript reduction after two doses, indel-mediated polymerase knockout in remaining cccDNA, and pgRNA as a validated biomarker collectively support a stronger eradication/functional-cure pathway narrative.
Market read
This is a high-conviction clinical catalyst for DTIL: first biopsy evidence of cccDNA elimination plus biomarker validation and an improving safety profile.
What to watch
Durability beyond ~1 year, consistency across broader populations, and whether pgRNA loss reliably predicts complete functional cure (not just replication suppression) remain unproven.
Background
ELIMINATE-B is testing PBGENE-HBV, a gene-editing therapy intended to directly eliminate cccDNA—the transcriptional template driving HBV replication.
Ticker impact
Precision BioSciences reported first clinical biopsy evidence that PBGENE-HBV directly eliminates/inactivates cccDNA in hepatitis B patients.
Near-term upside bias with volatility as investors price in Part 2 ELIMINATE-B and durability/withdrawal outcomes.
The article cites first-of-its-kind cccDNA elimination in liver biopsies, pgRNA-to-elimination linkage, durable HBsAg declines, and no dose-limiting toxicities—key catalysts for biotech valuation.
Market effects
Strengthens the gene-editing/functional-cure HBV thesis and may raise expectations for cccDNA-targeting approaches across the sector.
Primarily US biotech sentiment; could spill over to US-listed gene-editing and HBV peers via read-across.
HBV is global; breakthrough cccDNA elimination could attract international capital toward similar HBV eradication programs.
Counterpoint
Biopsy-confirmed cccDNA elimination is early (small cohorts, limited doses); investors may over-extrapolate before larger datasets and nucleoside-analog withdrawal results.
Key entities
- companyPrecision BioSciences
Reported first clinical biopsy evidence of direct cccDNA elimination/inactivation with PBGENE-HBV in ELIMINATE-B.
- programPBGENE-HBV
ARCUS genome-editing HBV therapy; showed cccDNA transcript reductions and indels disrupting viral polymerase function.
- regulatoryFDA Fast Track
Fast Track designation supports the company’s cccDNA/HBV eradication endpoint strategy.
